78075-83-9

Basic information

• Product Name: 1H-Pyrrole, 2-methyl-1-(phenylmethyl)-
• CAS NO: 78075-83-9
• Molecular Formula: C12H13N
• Molecular Weight: 171.242
• Mol File: 78075-83-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1H-Pyrrole, 2-methyl-1-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrole, 2-methyl-1-(phenylmethyl)-(78075-83-9)
• EPA Substance Registry System: 1H-Pyrrole, 2-methyl-1-(phenylmethyl)-(78075-83-9)

Safety Data

• Hazardous Substances Data: 78075-83-9(Hazardous Substances Data)

Upstream product

• 18159-24-5 1-benzyl-1H-pyrrole-2-carbaldehyde 
• 100-39-0 benzyl bromide 
• 2051-97-0 1-benzyl-1H-pyrrole 
• 626-96-0 4-oxopentanal 
• 100-46-9 benzylamine 
• 123-76-2 levulinic acid 
• 71208-75-8 1-benzyl-2-pyrrolyl 4,6-dimethyl-2-pyridyl ketone 
• 71208-76-9 2-(1-benzyl-2-pyrrolylmethyl)-4,6-dimethylpyridine 
• 1003-29-8 2-pyrrole aldehyde 
• 71381-49-2 2-(1-benzyl-2-pyrrolylmethyl)-1,4,6-trimethylpyridinium iodide 

Downstream Products

• 105235-19-6 1-benzyl-2-methyl-5-(4,5-dihydropyrrol-2-yl)pyrrole 
• 936571-93-6 1-benzyl-5-methyl-1H-pyrrole-2-carbaldehyde 
• 105235-21-0 11-benzyl-3-pentyl-2,4,10-trimethylprodigiosene hydrochloride 
• 105235-20-9 11-benzyl-3-ethyl-2,4,10-trimethylprodigiosene hydrochloride 
• 105283-33-8 1-benzyl-2-methyl-5-pyrrol-2-ylpyrrole 

Relevant articles and documents

Mild reduction with silanes and reductive amination of levulinic acid using a simple manganese catalyst

A manganese-based catalytic system using the commercially available complex [Mn(CO)5Br] was studied for the selective reduction of levulinic acid (LA) to 2-methyl-tetrahydrofuran (MTHF). We further studied the production of pyrrolidines via its reductive amination using silanes (phenylsilane and tetramethyldisiloxane). The results showed high efficiency and selectivity for this reaction leading to high yields using mild reaction conditions.

PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS

The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.

REARRANGEMENT OF 1-PIPERIDINOCYCLOPROPYL KETIMINES. A SYNTHESIS OF 2-SUBSTITUTED PYRROLES

On heating 1-(N-piperidino)cyclopropyl ketimines with HBF4, rearrangement to 2-substituted pyrroles takes place.